Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2018-11-10
Buyer: Oslo Universitetssykehus HF - Strategi og anskaffelsesavdelingen MTV
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33100000
Estimated value: 10873338 NOK
Award criteria: The most economic tender

Technical requirements: 75315 RAD KRE Institutt for kreftgenetikk og informatikk Sekvensator-NGS [RAD KRE Institute for Cancer Genetics and Informatics Sequencer - NGS]
Institutt for kreftgenetikk [the Institute for Cancer Genetics] will procure a sequencer/NGS/MPS. It must be a compact system with streamlined workflow with automated preparation of library, sequencing, bio-informatics analysis and complete report. The instrument must be able to run DNA and RNA isolated from FFPE tissue input quantity 1-10 ng with a kit from the one supplier for the entire workflow. The instrument will be used for research.
Institutt for kreftgenetikk [the Institute for Cancer Genetics] will procure a sequencer/NGS/MPS. It must be a compact system with streamlined workflow with automated preparation of library, sequencing, bio-informatics analysis and complete report. The instrument must be able to run DNA and RNA isolated from FFPE tissue input quantity 1-10 ng with a kit from the one and only supplier for the entire workflow. The instrument will be used for research.
The procurement also comprises signing a Framework Agreement for the purchase of equipment specific consumables. This Framework Agreement is ongoing and applies for as long as the equipment is in use.
All equipment offered must satisfy all relevant directives and standards. Documentation for this must be enclosed with the tender offer. Such documentation can for example be Declaration of Conformity (RUO). The instrument must have the possibility of sequencing output from 2 000 000 — 80 000 000 reads per run, with a minimum read length of 200 bases. The Contracting Authority must also have the possibility of upgrading the same instrument to be able to perform 130 000 000 reads per operation/run. Pure sequencing time must not take more than 2.5 hours, regardless of chip size, number of samples, kit type etc., i.e. one should be able to set up the next chip within 2,5 hours. The instrument should be able to run DNA and RNA isolated from FFPE tissue input amount 1-10 ng with a kit from the one and only supplier for the entire workflow. It should be a compact system of streamlined workflow with automated preparation of library, sequencing, bio informatic analysis and complete report. Possibility to run 200, 400 and 600 bp. As long single read reading lengths are particularly important for some of the desires applications, there must be the possibility of running 3 x 2 exomes per day on relevant instruments in the future if desired. The instrument must be able to incorporate MicroArray data and NGS data in one and the same report, and in the same software. For technical reasons, it is assumed that Life Technologies', part of Thermo Fisher Scientific AS, is the only supplier that can deliver in accordance with the requirements. The intention notice is pursuant to the public procurement regulations § 21-5. The terms in FOA [PPR] § 13-4 (2) and 13-1 (5) are considered met as well as the value of the full service contract for the instrument´s lifetime and equipment specific consumables.
7315 RAD KRE Institutt for kreftgenetikk og informatikk Sekvensator-NGS [RAD KRE Institute for Cancer Genetics and Informatics Sequencer — NGS]
The appeals deadline is 11 days after the prior information notice is announced. Deadline for appeals: Monday 19.11.2018, 12:00.


Winner: Lifetechnologies, en del av ThermoFisher Scientific
Award value: 10873338